Logo

Deltagen in Research Deal With Schering Institute, Introduces New Database

Feb 25, 2000
Premium

M

ENLO PARK, Calif.--Deltagen announced the signing of a DeltaSelect research agreement with Schering-Plough Research Institute to validate small molecule drug targets. Schering-Plough will provide target gene sequences to Deltagen, which will use its proprietary mammalian gene knockout and phenotypic analysis technologies to enable Schering-Plough to define each gene’s function in vivo. Financial terms of the agreement were not disclosed.

Separately, Deltagen launched its DeltaBase in vivo mammalian gene function database which enables pharmaceutical partners to access functional information on novel genes to facilitate development of new genomics-based medicines.

Filed under

Informatics
Breaking News
The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.